Product Information
ABILIFY 30 MG TABLET is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $26.2357 per EA under NDC 59148001113. Its NADAC has been published 470 times since Nov 28, 2013.
FDA first approved this application on Nov 15, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the ARIPIPRAZOLE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30 mg/1
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148001113
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
ARIPIPRAZOLEApproval Type
New Drug (NDA)
FDA Application
NDA021436FDA Approved
11/15/2002
TE Code
AB
On Market Since
11/15/2002
Pharmacological Classes
Price Statistics
The NADAC for ABILIFY 30 MG TABLET has been published 470 times since Nov 28, 2013, and over the history we have for it it has declined 14.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $26.2357 per EA |
|---|---|
| All-time high | $40.9832 (Oct 14, 2015) |
| All-time low | $26.1959 (Mar 18, 2026) |
| 52-week high | $26.4781 |
| 52-week low | $26.1959 |
| Median price | $40.4383 |
| Average price | $36.1614 |
| Largest weekly change | -35.5% (Apr 17, 2024) |
| Weeks tracked | 470 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ABILIFY 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ABILIFY 30 MG TABLET, manufactured by Otsuka America Pharmaceutical Inc., is $26.2357 per EA (NDC 59148001113), effective Aug 19, 2026.
How has the price of ABILIFY 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for ABILIFY 30 MG TABLET has declined 14.7%. It has been tracked across 470 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ABILIFY 30 MG TABLET?
Since Nov 28, 2013, the NADAC for ABILIFY 30 MG TABLET has ranged from a low of $26.1959 (Mar 18, 2026) to a high of $40.9832 (Oct 14, 2015), with a median of $40.4383 per EA.
Are there cheaper alternatives to ABILIFY 30 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ARIPIPRAZOLE 30 MG TABLET, is $0.1734 per EA — about 99% below ABILIFY 30 MG TABLET.
Who manufactures ABILIFY 30 MG TABLET?
ABILIFY 30 MG TABLET (NDC 59148001113) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.